NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer Journal Article
| Authors: | Chio, I. I. C.; Jafarnejad, S. M.; Ponz-Sarvise, M.; Park, Y.; Rivera, K.; Palm, W.; Wilson, J.; Sangar, V.; Hao, Y.; Öhlund, D.; Wright, K.; Filippini, D.; Lee, E. J.; Da Silva, B.; Schoepfer, C.; Wilkinson, J. E.; Buscaglia, J. M.; DeNicola, G. M.; Tiriac, H.; Hammell, M.; Crawford, H. C.; Schmidt, E. E.; Thompson, C. B.; Pappin, D. J.; Sonenberg, N.; Tuveson, D. A. |
| Article Title: | NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer |
| Abstract: | Pancreatic cancer is a deadly malignancy that lacks effective therapeutics. We previously reported that oncogenic Kras induced the redox master regulator Nfe2l2/Nrf2 to stimulate pancreatic and lung cancer initiation. Here, we show that NRF2 is necessary to maintain pancreatic cancer proliferation by regulating mRNA translation. Specifically, loss of NRF2 led to defects in autocrine epidermal growth factor receptor (EGFR) signaling and oxidation of specific translational regulatory proteins, resulting in impaired cap-dependent and cap-independent mRNA translation in pancreatic cancer cells. Combined targeting of the EGFR effector AKT and the glutathione antioxidant pathway mimicked Nrf2 ablation to potently inhibit pancreatic cancer ex vivo and in vivo, representing a promising synthetic lethal strategy for treating the disease. © 2016 Elsevier Inc. |
| Journal Title: | Cell |
| Volume: | 166 |
| Issue: | 4 |
| ISSN: | 0092-8674 |
| Publisher: | Cell Press |
| Date Published: | 2016-08-11 |
| Start Page: | 963 |
| End Page: | 976 |
| Language: | English |
| DOI: | 10.1016/j.cell.2016.06.056 |
| PROVIDER: | scopus |
| PUBMED: | 27477511 |
| PMCID: | PMC5234705 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 September 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work